Seminars in Nuclear Medicine
Volume 32, Issue 4 , Pages 276-292 , October 2002

Peptide and antibody imaging in lung cancer

  • Joset Machac

      Affiliations

    • Division of Nuclear Medicine, Department of Radiology, Mount Sinai Hospital, New York, NY. USA
    • Mount Sinai School of Medicine of New York University, New York, NY. USA
    • Corresponding Author InformationAddress reprint requests to Josef Machac, MD, Mount Sinai Medical Center, 1 Gustave Levy Place, Box 1141, New York, NY 10029.
    • ,
  • Borys Krynyckyi

      Affiliations

    • Division of Nuclear Medicine, Department of Radiology, Mount Sinai Hospital, New York, NY. USA
    • Mount Sinai School of Medicine of New York University, New York, NY. USA
    • ,
  • Chun Kim

      Affiliations

    • Division of Nuclear Medicine, Department of Radiology, Mount Sinai Hospital, New York, NY. USA
    • Mount Sinai School of Medicine of New York University, New York, NY. USA

References 

  1. Stoller JK, Ahmad M, Rice TW. Solitary pulmonary nodules. Cleve Clin J Med. 1988;55:68–71
  2. Templeton A, Jansen C, Lehr J, et al. Solitary pulmonary lesions: Computer aided differential diagnosis and evaluation of mathematical methods. Radiology. 1967;89:605–613
  3. Edwards F, Schaefer P, Callahan S, et al. Bayesian statistical theory in the preoperative diagnosis of pulmonary lesions. Chest. 1987;92:888–891
  4. Libshitz HI, McKenna RJ. Mediastinal lymph node size and lung cancer. AJR Am J Roentgenol. 1984;143:715–718
  5. Breitz HB, Sullivan K, Nelp WB. Imaging lung cancer with radio-labeled antibodies. In: Semin Nucl Med. 23:1993;p. 127–132
  6. Gould MK, MacLean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions. JAMA. 2001;285:914–924
  7. Higashi K, Seki H, Taniguchi M, et al. Bronchoalveolar carcinoma: False-negative results on FDG-PET. J Nucl Med. 1997;38:79P
  8. Duhaylongsod FD, Lowe VJ, Fujiwara T, et al. Differential diagnosis of lung tumor with positron emission tomography (FDG PET). J Thorac Cardiovasc Surg. 1995;110:130–139
  9. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med. 1996;37:943–948
  10. Adams S, Baum RP, Hertel A, et al. Metabolic (PET) and receptor (SPECT) imaging of well-and less well-differentiated tumours: Comparison with the expression of the Ki-67 antigen. Nucl Med Commun. 1998;19:641–647
  11. Pasquali C, Rubello D, Sperti C, et al. Neuroendocrine tumor imaging: Can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior?. World J Surg. 1998;22:588–592
  12. Sugawara Y, Braun DK, Kison PV, et al. Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: Preliminary results. Eur J Nucl Med. 1998;25:1238–1243
  13. Sugawara Y, Gutowski TD, Fisher SJ, et al. Uptake of positron emission tomography in tracers in experimental bacterial infections: A comparative biodistribution study of radiolabeled FDG, thymidine, L-methionine, 67Ga-citrate, and 125I-HAS. Eur J Nucl Med. 1999;26:333–341
  14. Shreve P, Steventon S, Deers E, et al. Oncologic diagnosis with 2[fluorine-18] fluoro-2-deoxy-D-glucose imaging: Dual-head coincidence gamma camera versus positron emission tomographic scanner. Radiology. 1998;207:431–437
  15. Serafini AN. From monoclonal antibodies to peptides and molecular recognition units: An overview. J Nucl Med. 1993;34:533–536
  16. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497
  17. (suppl) Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 1990;50:814–819
  18. Wahl RL, Parker CW, Philpott GW. Improved radioimaging and tumor localization with monoclonal F(ab)2. J Nucl Med. 1983;24:316–325
  19. Hertel A, Baum RP, Auerbach B, et al. Klinische Relevanz humaner Anti-Maus Antikoerper (HAMA) in der Immunszintigraphie. Nucklearmedizin. 1990;29:221–227
  20. Moffat FD, Pinsky CM, Hammershaimb L, et al. Clinical utility of external immunoscintigraphy with the IMMUN-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: Results of a pivotal, phase III trial. The Immunomedics Study Group. J Clin Oncol. 1996;14:2295–2305
  21. Keenan AM, Hurbert JC, Larson SM. Monoclonal antibodies in nuclear medicine. J Nucl Med. 1985;26:531–537
  22. Package insert. Dr. Karl Thomae GmbH, Boehringer Ingelheim International GmbH, DuPont Radiopharmaceutical Division, Ingelheim, Germany.
  23. Hornick JL, Sharifi J, Khawli LA, et al. Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors. J Nucl Med. 2000;41:355–362
  24. Hardman N, Lee Gill L, Winter de RFJ, et al. Generation of a recombinant human-mouse chimaeric monoclonal antibody directed against human carcinoembryonic antigen. Int J Cancer. 1989;44:424–433
  25. Hollinger P, Winter G. Diabodies: Small bispecific antibody fragments. Cancer Immunol Immunother. 1997;45:128–130
  26. Terskikh AV, Le Doussal JM, Crameri R, et al. “Peptibody”: A new type of high avidity binding protein. In: Proc Natl Acad Sci U S A. 94:1997;p. 1663–1668
  27. Bischof Delaloye A, Delaloye B. Radiolabeled monoclonal antibodies in tumor imaging and therapy: Out of fashion?. Eur J Med. 1995;22:571–580
  28. Minna JD, Higgins GA, Glatstein EJ. Cancer of the lung. In: deVita VT, Hellman S, Rosenberg SA editor. Cancer: Principles and Practice of Oncology. ed 2. Philadelphia, PA: JB Lippincott; 1985;p. 507–597
  29. Larson SM, Brown JP, Wright PW. Imaging of melanoma with I-131 monoclonal antibodies. J Nucl Med. 1982;24:123–129
  30. Perkins AC, Pimm MV, Morgan DAL, et al. 131I and 111In-labeled monoclonal antibody imaging of primary lung carcinoma. Nucl Med Commun. 1986;7:729–739
  31. Kalofonos HP, Sivolapenko GB, Courtenay-Luck NS, et al. Antibody guided targeting of non-small cell, lung cancer using 111In-labeled HMFGI F(ab')2 fragments. Cancer Res. 1988;48:1977–1984
  32. Schwartz A, Steinstrasser A. A novel approach to Tc-99m labeled monoclonal antibodies. J Nucl Med. 1987;28:721
  33. Said JW, Nash G, Tepper G, et al. Keratin proteins and carcinoembryonic antigen in lung carcinoma: An immunoperoxidase study of 54 cases with ultrastructural correlations. Hum Pathol. 1983;14:70–76
  34. Holden J, Churg A. Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant, mesothelioma. Am J Surg Pathol. 1984;8:277–279
  35. Krishnamurthy S, Morris JF, Antonovic R, et al. Evaluation of primary lung cancer with indium 111 anti-carcinoembryonic antigen (type ZCE-025) monoclonal antibody scintigraphy. Cancer. 1990;65:458–465
  36. Biggi A, Gianfranco B, Ferrigno D, et al. Detection of suspected primary lung cancer by scintigraphy with indium-111-anticarcinoembryonic antigen monoclonal antibodies (type FO23C5). J Nucl Med. 1991;32:2046–2068
  37. Bourguet P, Dazord L, Desrues B, et al. Immunoscintigraphy of human lung squamous cell carcinoma using an iodine-131 labeled monoclonal antibody (Po66). Br J Cancer. 1990;61:230–234
  38. Ihde DC, Hansen HH. Staging procedures and prognostic factors in small, cell carcinoma of the lung. In: Greco FA, Oldham RK, Bunn PA editor. Small Cell Lung Cancer. New York, NY: Grune & Stratton; 1981;p. 261–283
  39. Nelp WB, Griep RG, Salk D, et al. Staging of small cell cancer of the lung using Rc-99m labeled antibody (Fab). In: Haseman MK editors. Frontiers of Nuclear Medicine: Diagnostic Uses of Radiolabeled Monoclonal Antibodies. Washington, DC: American College of Nuclear Physicians; 1992;p. 15–20
  40. (abstr) Abrams P, Fer M, Faubion C, et al. A new procedure for staging small cell lung cancer (SCLC): Gamma, camera imaging using a technetium-99m labeled monoclonal antibody Fab. Am Soc Clin Oncol. 1990;9:A895
  41. Balaban EP, Walker BS, Cox JV, et al. Detection and staging of small cell lung carcinoma with a technetium-labeled monoclonal antibody. A comparison with standard staging methods. Clin Nucl Med. 1992;17:439–445
  42. Vansant JP, Johnson DH, O'Donnell DM, et al. Staging lung carcinoma, with a Tc-99m labeled monoclonal antibody. Clin Nucl Med. 1992;17:431–437
  43. Friedman S, Sullivan K, Salk D, et al. Staging non-small cell carcinoma of the lung using technetium-99m-labeled monoclonal antibodies. Hematol Oncol Clin North Am. 1990;4:1069–1078
  44. Rusch V, Macapinlac H, Heelan R, et al. NR-LU-10 monoclonal antibody scanning: A helpful new adjunct to CT in evaluating non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1993;106:200–204
  45. Vuillez JP, Moro D, Brichon PY, et al. Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med. 1997;38:507–511
  46. Reubi JC, Shaer JC, Markwalder R, et al. Distribution of somatostatin receptors in normal and neoplastic human tissues: Recent advances and potential relevance. Yale J Biol Med. 1997;70:471–479
  47. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716–731
  48. Oliaro A, Filosso PL, Bello M, et al. Neuroendocrine carcinomas of the lung and role of 111In-DTPA octreotide scintigraphy: Preliminary results. J Cardiovasc Surg. 1996;37:653–656
  49. Kirsh C-M, von Pawel J, Grau I, et al. Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma. Eur J Nucl Med. 1994;21:1318–1325
  50. O'Byrne KJ, Halmos G, Pinski J, et al. Somatostatin receptor expression in lung cancer. Eur J Cancer. 1994;30A:1682–1687
  51. Kwekkeboom DJ, Kho GS, Lamberts SWJ, et al. The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med. 1994;21:1106–1113
  52. Bombardieri E, Crippa F, Cataldo I, et al. Somatostatin receptor imaging of small cell lung cancer (SCLC) by means of 111In-DTPA octreotide scintigraphy. Eur J Cancer. 1995;31A:184–188
  53. Stokkel MPM, Pauwels EKJ. Octreotide scintigraphy for small cell lung carcinoma: Past, present or future?. Eur J Nucl Med. 1994;21:1276–1278
  54. Nilsson O, Kolby L, Wangberg B, et al. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumors. Br J Cancer. 1998;77:632–637
  55. Leitha T, Studnicka M, Marosi M, et al. The role of iodine-123-Tyr-3-octreotide scintigraphy in the staging of small-cell lung cancer. Nucl Med. 1993;34:1397–1402
  56. Maini CL, Tofani A, Venturo I, et al. Somatostatin receptor imaging in small cell lung cancer using indium-11-DTPA octreotide: A preliminary study. Nucl Med Commun. 1993;13:962–968
  57. Hochstenbag MMH, Heidendal GAK, Wouters EFM, et al. In-111 octreotide imaging in staging of small cell lung cancer. Clin Nucl Med. 1997;22:811–816
  58. Reisinger I, Bohuslavitzki KH, Brenner W, et al. Somatostatin receptor scintigraphy in small-cell lung cancer: Results of a multicenter study. J Nucl Med. 1998;39:224–227
  59. O'Byrne KJ, Ennis JT, Freyne PJ, et al. Scintigraphic imaging of small-cell lung cancer with [indium-111] pentetreotide, a radiolabelled somatostatin analogue. Br J Cancer. 1994;69:762–766
  60. Macauly VM, Smith IE, Everard MJ, et al. Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer. Br J Cancer. 1991;64:451–456
  61. Weinman P, Crestani B, Tazi A, et al. 111In-pentetreotide scintigraphy in patients with Langerhans' cell histiocytosis. J Nucl Med. 2000;41:1808–1812
  62. Lonneux M, Jamar F, Leners N, et al. Uptake of In-111 pentetreotide by pleural plaques. Clin Nucl Med. 1998;23:298–301
  63. Olmos RAV, vanZandwijk N, Boersma LJ, et al. Radiation pneumonitis with indium-111-pentetreotide. J Nucl Med. 1996;37:584–588
  64. Vallabhajosula S, Moyer BR, Lister-James J, et al. Preclinical evaluation of technetium-99m-labeled somatostatin receptor binding peptides. J Nucl Med. 1996;37:1016–1022
  65. Virgolini I, Leimer M, Handmaker H, et al. Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829. Cancer Res. 1998;58:1850–1859
  66. Virgolini I, Pangerl T, Bischof C, et al. Somatostatin receptor expression in human tissues: A prediction for diagnosis and treatment of cancer. Eur J Clin Invest. 1997;27:645–647
  67. O'Byrne K, Carney D. Somatostatin and the lung. Lung Cancer. 1993;10:151–172
  68. Fujita T, Yamaji Y, Sato M, et al. Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2, in human lung cancer cell lines. Life Sci. 1994;55:1797–1806
  69. Blum JE, Handmaker H, Rinne NA. The utility of a somatostatin-type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules. Chest. 1999;115:224–232
  70. Blum J, Handmaker H, Lister-James J, et al. A multicenter trial with a somatostatin analog 99mTc depreotide in the evaluation of solitary pulmonary nodules. Chest. 2000;117:1232–1238
  71. (suppl) Gambhir SS, Shephard JE, Handmaker H, et al. Analysis of the cost-effectiveness of a somatostatin analog-Tc99m-depreotide (NeoTect) in the scintigraphic evaluation of solitary pulmonary nodules (SPN). J Nucl Med. 1999;40:57P
  72. Kernstine KH, Kahn D, Menda Y, et al. A new technique for staging potentially-resectable lung cancer: Neotect SPECT Tc-99m (NeoT) compared with F-18 FDG. In: Proc Am Soc Clin Oncol. 20:2001;p. 1352
  73. Breeman WA, Hofland LJ, Bakker WH, et al. Radioiodinated somatostatin analogue RC-160: Preparation, biological activity, in vivo application in rats and comparison with [123I-Tyr3] octreotide. Eur J Nucl Med. 1993;20:1089–1094
  74. Breeman WA, Hofland LJ, van der Pluijm M, et al. A new radiolabeled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: Preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1] octreotide. Eur J Nucl Med. 1994;21:328–335
  75. Banks WA, Shally AV, Barrera CM, et al. Permeability of the murine blood brain barrier to some octapeptide analogues of somatostatin. In: Proc Natl Acad Sci U S A. 10:1990;p. 431–438
  76. Decristoforo C, Mather SJ. Technetium-99m somatostatin analogues: Effect of labelling methods and peptide sequence. Eur J Nucl Med. 1999;26:869–876
  77. Decristoforo C, Moncayo R, Riccabona G, et al. Preclinical and initial patient studies of a new Tc-99m octreotide derivative based on the HYNIC-system in comparison with 111In-DTPA-octreotide. Eur J Nucl Med. 2000;27:S87
  78. Traub T, Petkov V, Ofluoglu S, et al. 111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung. J Nucl Med. 2001;42:1309–1315
  79. Virgolini I, Patri P, Novotny C, et al. Comparative somatostatin receptor scintigraphy, using In-111-DOTA-lanreotide and In-111 DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol. 2001;12:541–545
  80. Okarvi SM. Recent progress in fluorine-18 labelled peptide radiop-harmaceuticals. Eur J Nucl Med. 2001;28:929–938
  81. Guhlke S, Wester HJ, Bruns C, et al. (2-[18F]Fluoropropionyl-(D)phe1)-octreotide, a potential radiopharmaceutical for quantitative somatostatin receptor imaging with PET: Synthesis, radiolabelling, in vitro validation and biodistribution in mice. Nucl Med Biol. 1994;21:819–829
  82. Wester HJ, Brockman J, Roesch F, et al. PET pharmacokinetics of F-18-octreotide: A comparison with Ga-67 DFO- and Y-86-DTPA octreotide. Nucl Med Biol. 1997;24:275–286
  83. Virgolini I, Yang Q, Li S, et al. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res. 1994;54:690–700
  84. Virgolini I, Raderer M, Kurtaran A, et al. Vasoactive intestinal peptide-receptor imaging for the localization, of intestinal adenocarcinomas and endocrine tumors. N Engl J Med. 1994;331:1116–1121
  85. Virgolini I, Raderer M, Kurtaran A, et al. 123I-vasoactive intestinal peptide (VIP) receptor scanning: Update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. Nucl Med Biol. 1996;23:685–692
  86. Raderer M, Kurtaran A, Leimer M, et al. Value of peptide receptor scintigraphy using 213I-vasoactive intestinal peptide and 111In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University experience, 1993–1998. J Clin Oncol. 2000;18:1331–1336
  87. Virgolini I, Kurtaran A, Raderer K, et al. Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med. 1995;36:1732–1739
  88. Reubi JC. In vitro identification of vasoactive intestinal peptide receptors in human tumors: Implications for tumor imaging. J Nucl Med. 1995;36:1846–1853
  89. Reubi JC, Schaer JC, Waser B. Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res. 1997;57:1377–1386
  90. Hennig IM, Laossue JA, Horisberger U, et al. Substance P receptors in human primary neoplasms. Int J Cancer. 1995;61:786–792
  91. Behr TM, Gotthardt M, Barth A, et al. Imaging tumors with peptide-based radioligands. Q J Nucl Med. 2001;45:189–200
  92. Reile H, Armatis PE, Shally AV. Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: Internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells. Prostate. 1994;25:29–38
  93. Moody TW, Carney DN, Cuttiteta F, et al. High affinity receptors for bombesin/GRP-like peptides on human small cell lung cancer. Life Sci. 1985;37:105–113
  94. Wood SM, Wood JR, Ghatei MA, et al. Bombesin somatostatin and neurotensin-like immunoreactivity in bronchial carcinoma. J Clin Endocrinol Metab. 1981;53:1310–1312
  95. Toi-Scott M, Jones CL, Kane MA, et al. Clinical correlates of bombesin-like peptide receptor subtype expression in human lung cancer cells. Lung Cancer. 1996;15:341–354
  96. Chaudhry A, Carrasquillo JA, Avis IL, et al. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. Clin Cancer Res. 1999;5:3385–3393
  97. Kelley MJ, Linnoila RI, Avis IL, et al. Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest. 1997;112:256–261
  98. Breeman WA, DeJong M, Bernard BF, et al. Pre-clinical evaluation of [111In-DTPA-Pro(2), Tyr(4)] bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer. 1999;83:657–663
  99. Baidoo KE, Lin KS, Zhan Y, et al. Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconjug Chem. 1998;9:218–225
  100. Cuartero-Plaza A, Martinez-Miralles E, Rosell R, et al. Radiolocalization of squamous lung carcinoma with I-131-labeled epidermal growth factor. Clin Cancer Res. 1996;2:13–20
  101. Lafrenie RM, Gallo S, Podor TJ, et al. The relative roles of vitronectin receptor, E-selectin and alpha 4 beta 1 in cancer cell adhesion to interleukin-1-treated endothelial cells. Eur J Cancer. 1994;30A:2151–2158
  102. Breitz HB, Sullivan K, Nelp WB, et al. Imaging lung cancer with radiolabeled antibodies. In: Semin Nucl Med. 23:1993;p. 127–132

PII: S0001-2998(02)80019-8

doi: 10.1053/snuc.2002.126053

Seminars in Nuclear Medicine
Volume 32, Issue 4 , Pages 276-292 , October 2002

Article Tools